# A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors

> **NCT04045496** · PHASE1 · COMPLETED · sponsor: **Jacobio Pharmaceuticals Co., Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Non-small Cell Lung Cancer
- Colorectal Cancer
- Pancreatic Ductal Carcinoma
- Esophageal Squamous Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Breast Cancer
- Other Solid Tumors

## Interventions

- **DRUG:** JAB-3312

## Key facts

- **NCT ID:** NCT04045496
- **Lead sponsor:** Jacobio Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-26
- **Primary completion:** 2022-12-16
- **Final completion:** 2022-12-16
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04045496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04045496, "A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04045496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*